Klaria Pharma: A directed convertible loan issue and a rights issue totaling SEK74.8m - Redeye

Redeye comments on Klaria’s announcement earlier today regarding a SEK9.7m directed convertible loan issuance and a SEK65.1m rights issue. While being highly dilutive measures, we view these developments as well-aligned with Klaria’s strategic shift from R&D to commercialization, anchored by the forthcoming launch of Sumatriptan Alginate Film.

Länk till analysen i sin helhet: https://www.redeye.se/research/1112843/klaria-pharma-a-directed-convertible-loan-issue-and-a-rights-issue-totaling-sek74-8m?utm_source=finwire&utm_medium=RSS